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แบ่งเป็น 2 ระยะ ระยะที ่1 การวเิคราะห์สถานการณ์ระบบการพจิารณารบัรองฯ 
โดยเกบ็ขอ้มลูจากเอกสาร การสมัภาษณ์เจา้หน้าทีร่บัผดิชอบการรบัรองมาตรฐาน
ฯ ส านกังานคณะกรมการอาหารและยา (อย.) และการสมัภาษณ์กลุม่ผูร้บัอนุญาต
น าเขา้ ส่วนระยะที ่2 เป็นการพฒันาระบบการพจิารณารบัรองฯ ใหเ้หมาะสมกบั
ประเทศไทย เก็บขอ้มลูจากการสมัภาษณ์ผูบ้รหิารของ อย. ทีม่ปีระสบการณ์ดา้น
ระบบการพิจารณารบัรองฯ วิเคราะห์ข้อมูลโดยใช้ ความถี่ ร้อยละ และการ
วเิคราะห์เนื้อหา ผลการศึกษา: พบว่าการพจิารณารบัรองฯ ด าเนินงานล่าช้า
เนื่องจากพบขอ้บกพรอ่งของเอกสารประกอบการพจิารณารบัรองฯ โดยเอกสารที่
พบขอ้บกพร่องมากทีสุ่ด คอื Plant Master File โดย อย. ไดแ้ก้ไขโดยจดัท าคูม่อื
ประชาชน แต่ยงัพบว่ามผีูร้บัอนุญาตฯ รอควินัดหมายตรวจสอบเอกสารเบื้องตน้




พิจารณารบัรองฯ ที่ได้นี้จ าเป็นต้องพฒันาเป็น 2 ระยะ โดยระยะสัน้ คือ การ
จดัการเบื้องตน้ภายใน อย. ส่วนระยะยาว คอื การวางแผนพฒันาระบบและแผน
งบประมาณเพือ่คุม้ครองผูบ้รโิภคในอนาคต สรปุ: ระบบการพจิารณารบัรองฯ ที่
เหมาะสมกบัประเทศไทยทีไ่ด ้ยงัต้องพฒันาอย่างต่อเนื่อง อย.ควรพฒันาทัง้ใน
สว่นการสนบัสนุนการท างานของเจา้หน้าที ่และผูร้บัอนุญาตฯ  
ค าส าคญั: ระบบการพจิารณารบัรองมาตรฐาน, สถานที่ผลติยาในต่างประเทศ, 





Objective:  To explore and develop the GMP accreditation of oversea 
manufacturers suitable for Thailand. Methods: This study used an integrated 
research method.  In phase 1, we performed document research on 
application and interviews on officers and group interviews on licensees.  In 
phase 2, we performed interviews on executive officers of Thai Food and 
Drug Administration (FDA)  who had experiences about GMP accreditation 
by purposive sampling. The data were analyzed using frequency, percentage 
and content analysis.  Results:  GMP accreditation approval process was 
delayed mainly because of application defects especially Plant Master File 
and a large number of applications were submitted. Public manual for GMP 
accreditation was made by Thai FDA.  Even though the process was 
improved but the application process was still delayed because of limited 
workforce to inspect the documents.  Defective documents and subsequent 
re-submission still slowed the whole process down. Informants reported that 
GMP accreditation process should be improved in 2 phases.  In short- term 
phase, organization management of the FDA should be improved.  In long-
term phase, and plan for consumer protection should be developed. 
Conclusion: GMP accreditation approval process of oversea manufacturers 
suitable for Thailand should be improved to support the work of officers and 
the import licensees.  
Keywords:  GMP accreditation, oversea manufacturer, approval, good 
manufacturing practice   
 
 
   
Introduction 
The Food and Drug Administration (FDA) of Thailand had 
developed and launched the first Good Manufacturing Practice 
(GMP) of Medicinal Products in 1978 as guided by the World 
Health Organization (WHO). In 1984, Thai FDA had promoted 
industrial sectors to develop the standards of drug 
manufacturing, and GMP certificated firms that passed GMP 
inspections.  This policy had been continued until June 5, 
2003, the Ministry of Public Health (MOP) mandated all local 
pharmaceutical firms producing modern medicinal products to 
comply with the GMP. 1 With the effort to join the 
pharmaceutical inspection cooperation scheme (PICS) which 
is an international co-operative committee for developing GMP 
inspection standards toward the international one, the MOP 
revised the GMP and mandated the compliance into effect 
since October 5, 2 0 1 2 .  Since there was a change in 
manufacturing control such as legal enforcement and GMP 
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details, local pharmaceutical firms have been forced to 
improve pharmaceutical quality accreditation which could 
result in international quality of pharmaceutical products.  
In Thailand, pharmaceutical product market is highly 
competitive.  Low-cost finished pharmaceutical products have 
been imported from various countries such as the People’ s 
Republic of China, India, and South Korea, with suspected 
quality. 2 Vigilance on finished product quality on domestic 
manufacturers is therefore insufficient to assure the quality of 
the products available in the country.  With such premise, 
nondomestic pharmaceutical manufacturers of the products 
imported to Thailand are also subject to quality accreditation 
to hold GMP standards at least equal to those mandatory to 
local manufacturers.  The Thai FDA thus issued the GMP 
Accreditation of an Oversea or Non-Domestic Manufacturer 
which was enforced since October 1, 2012.  As a result, 
registration process of imported products from oversea 
manufacturers has been changed.  Specifically, nondomestic 
manufacturers whose finished products have not been 
registered with the Thai FDA must be accepted by the agent 
before applying for the import of the finished products to the 
country.  
With such legal requirement, import licensees are required 
to file quality accreditation documents mandatory by GMP 
standards for nondomestic manufacturers to the FDA for 
accreditation before the registration of the imported products.3 
The process is depicted in Figure 1.  
To get accreditation for oversea manufacturers, the import 
licensee usually submitted relatively similar documents to two 
units separately, but almost simultaneously, namely the Pre-
marketing Control Unit and the Post-marketing Control Unit of 
the Thai FDA ( Figure 1) .  Specifically, the Post-marketing 
Control Unit examined the manufacturer plant information 
based on GMP standards.  Once the plant quality was 
approved, the licensee was given the manufacturer approval 
letter. This letter was an additional piece of document referred 
to as the “plan information” that the licensee needed to submit 
to the Pre-marketing Control Unit in addition to the first set of 
submitted documents. The Pre-marketing Control Unit usually 
reviewed product information especially quality, safety and 
efficacy of the finished products, in addition to the “ plant 
information”  additionally submitted later.  The final stage was 
the registration number of the imported finished product 
granted by the Pre-marketing Control Unit.  
Based on the process mentioned above, with no 
collaborated document sharing between the Pre- marketing 
Control Unit and the Post-marketing Control Unit, the licensee 
unfortunately had to submit two relatively similar documents 
almost simultaneously to the two units.  The duration until 
getting approval from the Post-marketing Control Unit was 
usually shorter than the one from the Pre-marketing Control 
Unit.  In addition, the licensee needed to submit the approval 
letter from the Post- marketing Control Unit to the Pre-
marketing Control Unit by themselves because of no sharing 
or transferring of documents between the two units (Figure 1).  
 
 
 Figure 1  The registration process for importation of 
pharmaceutical finished products to Thailand.  
Based on the execution from October 1, 2012 to March 
31, 2016 enforced by the new regulations for accreditation on 
oversea manufacturers, several issues had been found. 4 For 
example, many filed submissions for accreditation on oversea 
manufacturers had been rejected. In addition, there had been 
a lack of officers to sufficiently handle submission filing, and 
to provide information, answer, and advice for the import 
licensees.  In the past, the approval was done based only on 
evaluation of filed documents; no on- site inspection on 
oversea manufacturers was done even with a suspect on the 
manufacturer’ s quality.  This is because there has been no 
rules allowing collecting on- site inspection fees from the 
oversea manufacturers. Furthermore, there has been no rules 
for import licensees to follow once the accreditation of their 
oversea manufacturers is approaching expiration within 3 
years.  
Other studies have shown the process of accreditation for 
oversea manufacturers in certain countries which are different 
from that of Thai FDA.  In Australia, the Therapeutic Goods 
Administration has Regulatory Guidelines Good 
Manufacturing Practice ( GMP)  Clearance for Overseas 
Manufacturers demand different documents necessary for 
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accreditation of oversea manufacturers according to countries. 
The discrepancy of the required documents among various 
countries depends on their trade agreement with Australia, 
activities in the oversea manufacturers, the finished products 
produced, and the GMP regulatory agents in the oversea 
countries. 5 The maintenance of accreditation is clearly 
specified by Australia’s Therapeutic Goods Administration.5 In 
Singapore, fees for on-site inspection has been mandated with 
fee amounts according to the locations of the oversea 
manufacturers. 6  In Thailand, the accreditation for oversea 
manufacturers has been in a relatively early stage.  The have 
been a large number of problems such as personnel, rules 
and regulations, standard procedure, and operational 
outcomes.  With the concern and need to improve the 
accreditation process, the researchers aimed to understand 
the process and problems of accreditation for oversea 
manufacturers of the imported pharmaceutical products. 
Understanding on the issue could be useful for improving the 
accreditation process suitable for Thailand which was defined 
as the one that is faster, more efficient, and more compliant 
to the GMP of individual countries of the oversea 
manufacturers.  
     
Methods 
 
This study was a cross-sectional analysis and was divided 
into two phases, specifically 1) situational analysis on the Thai 
FDA’ s existing accreditation process for the oversea 
manufacturers, and 2)  the analysis on the proposed 
accreditation process suitable for Thailand. 
In phase one or situational analysis, accreditation on 
oversea manufacturers of various countries was examined 
qualitatively and quantitatively.  First, by means of 
documentary research, issues and/or problems were extracted 
from accreditation application documents submitted for 
inspection, results of document inspection, reports of 
accreditation process. From the issues and/or problems found, 
the questions regarding problems, issues and possible 
solutions for interviews were formed.  The semi- structured or 
guided interviews were performed on two groups of 
informants, specifically ( 1)  individual interviews on 5 FDA 
officers in the accreditation process and 3 external experts in 
the accreditation ( a total of 8 informants) , and ( 2)  group 
interview on 9 import licensees (or delegates) consisting of 3 
accredited and the other 6 not accredited.  
The data obtained in the first phase were detailed 
situations and related problems, and possible solutions. Data 
were analyzed using descriptive statistics including frequency 
and percentage. Qualitatively, content analysis was performed 
to explore themes emerging from the interview content of 
accreditation process for oversea manufacturers suitable for 
Thailand.  Based on the findings, the proposed accreditation 
process and possible solutions were drafted for the second 
phase of the study.  
In the second phase, the proposed accreditation process 
and possible solutions were further tested for possibility or 
appropriateness by opinions from 3 experts which were Thai 
FDA executives with knowledge, understanding and 
experience in accreditation process. These expert informants 
were selected by purposive sampling.  Data collection was 
done by means of a semi-structured or guided interview. Their 
opinions and recommendations were analyzed by ways of 
content analysis and summarized.  
This study was approved by the Ethics Committee for Human 
Study, Faculty of Pharmacy, Silpakorn University (approval date: 




Phase 1: Situation of the existing accreditation process  
Accreditation process for oversea manufacturers was 
based on the data from October 2015.  The process could be 
divided into 4 steps specifically document preparation as shown 
in Table 1, appointment with the officer for accreditation 
application document inspection, and decision making by the 
committee for accreditation with or without the need for on-site 
inspection (Figure 2).  
In this situational analysis, problems and proposed 
solutions in the process of accreditation were identified as 
follows. First, there was a lack of FDA workforce especially those 
to preliminarily inspect the filed documents. It was found that from 
August 1, 2015 to September 30, 2016, despite two more teams 
added to the existing five teams of officers (two or more persons 
for each team) for preliminary inspection of documents, there was 
a delayed inspection among 155 of 260 submissions (59.61%) . 
All relevant FDA officers interviewed agreed that more personnel 
should be added to sufficiently handle the workload.  However, 
only one of the three FDA executive experts agreed with such 
solution. To improve the accreditation process with no additional 
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workforce, the three experts also proposed risk management, 
systematic thinking process, and information technology. 
 
 Table 1  List of documents for GMP accreditation 
request for oversea manufacturers for the imported finished 
pharmaceutical products.   
Oversea manufacturers approved by 
PICS Member 
Oversea manufacturers NEVER approved 
by PICS Member 
1. A request letter for accreditation approval  1. A request letter for accreditation approval 
2. A list of finished pharmaceutical products 
manufactured for GMP accreditation request 
of oversea manufacturer  
2. A list of finished pharmaceutical products 
manufactured for GMP accreditation request of 
oversea manufacturer 
3. Plant Master File for PICS member or 
Certified/Audited by PICS 
3. Plant Master File for non-PICS member 
4. Report on the latest GMP inspection results 
by country-specific regulatory agency or 
other acceptable international regulatory 
agency (if any) 
4. Report on the latest GMP inspection results by 
country-specific regulatory agency or other 
acceptable international regulatory agency (if 
any) 
5. A photocopy of the latest Certificate of GMP 
issued by government agency, private 
agency, or other acceptable international 
regulatory agency, or other comparable 
certificates issued by acceptable government 
or private agencies. 
5. A photocopy of the latest Certificate of GMP 
issued by government agency, private agency, 
or other acceptable international regulatory 
agency, or other comparable certificates issued 
by acceptable government or private agencies. 
6. A form to check for document completion or 
the Plant Master File for PICS member or 
Certified/Audited by PICS 
6. A form to check for document completion or the 
Plant Master File for Non PICS member or 
Certified/Audited by PICS, and manufacturing 
details of the imported pharmaceutical products 
especially plant, machines, devices, and plant 
layout 
 7. Details of the imported pharmaceutical products 
especially plant, machines, devices, and plant 
layout (for oversea manufacturers inspected by 





 Figure 2  The GMP accreditation process for oversea 
manufacturers of Thailand FDA.  
 
Second, it was found that accreditation process for 
oversea manufacturers was unclear.  Once approved, the 
oversea manufacturer GMP accreditation lasted only 3 years, 
while the registration number of the imported products was 
life-long, i.e., no expiration. It was found that the process was 
divided into three steps ( 1)  the initiative of the process 
(October 1, 2012 to July 31, 2015), (2) the modification of the 
process according to the public manual on accreditation 
(August 1, 2015 to September 30, 2016), and (3) the addition 
of the workforce and the modification of appointment for the 
preliminary document inspection.  In addition, there had been 
unclear rules on accreditation extension, accreditation 
amendment, temporary accreditation suspense, accreditation 
discontinuation, and on- site inspection of the oversea 
manufacturers.  These problems were agreed by all 
interviewees and experts. To alleviate these problems, it was 
recommended that more elaborate rules and regulations to 
handle all steps and personnel of the accreditation process be 
developed including preliminary document inspection, on- site 
oversea manufacturer inspection, accreditation status 
maintenance, accreditation extension, and accreditation 
discontinuation.  
Regarding the performance of inspecting the document, 
11. 76% of the interviewees agreed that the problem existed 
( i. e. , 2 external experts of 17 interviewees) .  Of the 17 
interviewees, 52. 94%  of them which were all 9 import 
licensees reported that it was unforeseeable to know what 
kind of additional documents the officer would ask for.  They 
recommended that clear and specific rules on document 
inspection be developed, and officers relevant to the process 
be trained before launching and periodically thereafter.  
In terms of document inspection, 5 officers and 3 experts 
of the total of 17 interviewees (47.06%)  reported that it was 
impossible to detect fraud or fabricated documents regarding 
oversea manufacturers.  They proposed that these filed 
documents need approval from reputable international 
agencies.  In addition, a database should be developed for 
vigilance in case of fraud documents.  
It was found that there was an unfair control on the 
domestic manufacturers compared to their oversea 
counterparts. While domestic manufacturers had been on-site 
inspected periodically, those oversea ones had not been so 
by the government PICS agents. For oversea manufacturers, 
Thai FDA only inspected documents for GMP standards 
compliance.  There was a recommendation that this problem 
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could be relieved by on- site inspection of oversea 
manufacturers for those never been inspected for GMP by 
PICS related regulatory agencies in their own countries.  This 
recommendation was agreed by all 4 experts, 1 of 4 officers, 
and 5 of 9 import licensees resulting in 10 of 17 agreement 
rate, or 58. 82%.  Therefore, it was proposed that Thai FDA 
should establish an annual oversea inspection schedule in 
addition to the plan to enhance the performance and potential 
of the workforce, as well as the plan to outsource experts for 
oversea manufacturer on-site inspection.  
The submission of accreditation request for oversea 
manufacturers was also an obvious, if not prevalent, problem. 
In duplicate addition to the submission to the Post-marketing 
Control Unit, once the oversea manufacturer was accredited, 
documents similar to the first submission was redundantly 
requested by the Pre-marketing Control Unit.  The problem 
was agreed upon by 88. 24%  of the interviewees ( 3 of 4 
experts, 3 of 4 officers, and all 9 import licensees). To relieve 
the problem, they proposed that a database of oversea 
manufacturers with their filed documents should be 
developed.  This database should be easy for retrieval and 
update for all involving FDA personnel and units so that the 
re-submission of documents is unnecessary. This solution was 
agreed by 88. 23% of the interviewees (all 4 experts, all 8 
officers, and 7 of 9 import licensees).  
It was a long waiting list for appointment with the officers 
during August 1, 2015 to September 30, 2016.  Based on the 
public manual on accreditation process available during that 
period of time, import licensees were guided to contact the 
officer at the Post-marketing Control Unit for the further in-
person appointment.  The date and time for the in- person 
appointment for preliminary document inspection was 
supposed to be e- mailed to the licensee within 7 days. 
Unfortunately, it was found there had been as high as 155 of 
a total 260 accreditation requests in the waiting list for 
preliminary document inspection (59.61%). The waiting time 
till the in-person preliminary document inspection was usually 
2 to 4 months. This problem was agreed upon by 82.35% of 
the interviewees ( 1 of 4 experts, all 4 officers, and all 9 
licensees) .  They suggested internet-based e- submission for 
preliminary document inspection instead of in- person 
appointment, so that the burden on a limited number of 
officers could be lessened and the waiting list could be 
shortened.  
The next problem was incomplete documents.  The most 
incomplete document was found in Plant Master File part (73 
of 80 accreditation request submissions, or 91.25%), followed 
by Certificate of GMP ( 46 of 80 accreditation request 
submissions, or 57. 50%) , pharmaceutical items for approval 
under the accreditation of oversea manufacturers (40 of 80 
accreditation request submissions, or 50.00%), and the latest 
report on GMP inspection results ( 40 of 80 accreditation 
request submissions, or 50.00%). Since as high as 91.25% of 
the submitted documents were found with at least one defect, 
further burden could be expected.  This was because the 
import licensees needed to re- submit the documents to 
replace the defective ones and the officers needed to inspect 
them unnecessarily.  
In addition, for import licensees who could not re- submit 
the documents before the deadline after the notification of 
incomplete documents, their accreditation request could 
unfortunately be rejected.  This could be even more 
problematic for documents that needed to obtain from the 
oversea manufacturers since the manufacturer could have no 
such documents or the documents were considered a private 
intellectual property not supposed to share. This problem was 
agreed upon by 70.59% of the interviewees (all 4 experts, all 
4 officers, and 4 of 9 licensees). The majority of interviewees 
( 88. 23% )  agreed that fewer documents necessary for 
evaluation should be required (3 of 4 experts, 3 of 4 officers, 
and 2 of 9 import licensees). In addition, all 3 FDA executive 
experts agreed that the list of documents did not adequately 
reflect the performance of GMP inspection on oversea 
manufacturers.  They also suggested that risk management 
should be used to improve the accreditation process and the 
relevant list of required documents.  However, they insisted 
that the requests with no crucial documents should be 
rejected.   
The last problem was that there was a large proportion of 
submitted accreditation requests that were ignored by the 
import licensees. From October 1, 2012 to July 31, 2015, 108 
of 256 submissions (42.19%) were ignored by the licensees. 
A lack of understanding in the accreditation process and the 
required documents was mostly the reason of such 
discontinuation or withdrawal.  The problem of a lack of 
knowledge and understanding was agreed upon by 70.59% of 
the interviewees (all 4 experts, all 4 officers, and 4 of 9 import 
licensees) .  In addition, all 3 FDA executive experts agreed 
with the solutions acquired from interviews, group interviews, 
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and document study. They also proposed the additional easy 
access to the database, advice, and forms with more 
accessible website, training, and media for E- learning.  They 
though that such improvement could help submission 
discontinuation or withdrawal.  The solutions to the problems 
emerging from document study, interviews with FDA officers 
and experts, group interviews with import licensees were used 
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Phase 2:  Development of accreditation process for 
oversea manufacturers of Thai FDA  
The proposed solutions from the first phase of the study, 
accompanied with results from further interview with FDA 
executive experts, could be used to form the new accreditation 
process for oversea manufacturers ( first phase)  as 
summarized in Figure 4.  The details of the newly developed 
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First, the module of advice service to import licensees 
should be separated from the other regular service, i. e. , 
document inspection. Second, internet-based technology such 
as E-book E-Learning could be in place to help the working 
process of the officers.  Third, the oversea manufacturers 
should be approved for accreditation before the registration of 
imported finished products could be requested so that burden 
and expense in the registration process could be reduced. 
Fourth, risk management should be in place to select 
submitted documents suitable for the given duration of 
inspection to avoid submission discontinuation or withdrawal. 
Fifth, Thai FDA should consider outsourcing external experts 
on inspection on oversea manufacturers to alleviate the 
burden on and improve the potential of the existing workforce. 
Last, to be transparent and fair for the import licensees and 
the oversea manufacturers, appeal process should be in 
place.  
 
Structure, process and outcomes of the accreditation 
process of oversea manufacturers  
Based on the findings previously mentioned, the 
improvement of accreditation process for oversea 
manufacturers could be summarized based on the concept of 
structure, process and output in two phases namely short- and 
long-term phases as follows.  
In the short-term phase, the managerial change within the 
relevant units of Thai FDA was proposed.  In terms of 
structure, the training for systematic thinking for personnel 
should be implemented. This could help manage the workflow 
more efficiently, especially the on- site inspection on oversea 
manufacturers and the document inspections with comparable 
standards among various evaluators.  On the other hand, 
import licensees should also be educated and trained more 
about the process of and documents necessary for 
accreditation request.  For learning materials, manuals and 
training sessions should be created and more readily available 
especially online e- learning materials in Thai and English 
language.  Finally, accreditation website should be improved 
for a better access.  
For the process aspect of the structure- process- output 
framework, protocols should be more elaborate to cover all 
steps of accreditation request including document inspection, 
on- site inspection of oversea manufacturers, and 
maintenance, extension and withdrawal of accreditation 
status.  Database of oversea manufacturers should be 
developed for a better access and retrieval not only for import 
licensees, but also for officers in Post- and Pre-market Control 
Units as well.  This database could help duplicate submission 
of documents for those oversea manufacturers already 
accredited.  The database could also be useful for officers to 
use for vigilance on fraud or fabricated documents. Regarding 
the working flow, risk management should be employed to 
prevent and minimize risks potentially found in the 
manufacturing as guided by the GMP standards.  Risk 
management could help evaluate the tasks where various 
factors of all involving countries are taken into account such 
as the latest inspection results, regulatory agents of the 
countries, bilateral trade agreement with Thailand, location of 
the oversea manufacturers, the country’ s GMP standards, 
type of finished pharmaceutical products, and the time of 
inspection.  
Lastly, for the output component of the structure-process-
output framework, the number of accredited oversea 
manufacturers as well as the GMP inspection on the domestic 
manufacturer was the crucial output of the improvement.  
For the long- term phase, development of system and 
budget for future consumer protection was planned.  It was 
suggested that have a plan for on- site inspection on oversea 
manufacturers never been inspected by their own regulatory 
agents in countries of PICS members.  It was also 
recommended that international agreement on mutual 
recognition on GMP evaluation results among PICS countries 
should be made.  This could alleviate the burden of on- site 
inspection on oversea manufacturers.  In addition, online e-
submission for accreditation request should be developed. 
Finally, there should be persons specifically assigned for 
providing advice on the accreditation process.  This could 
reduce burden on the whole workforce and provide more 
accurate information to the public. 
 
Discussions and Conclusion  
 
This study explored the problems and possible solutions 
in the development of accreditation process for oversea 
manufacturers of the finished pharmaceutical products. 
Further discussions are as follows.  First, risk management 
was proposed to improve the accreditation process to for a 
more efficient and less time- consuming protocol for products 
with different risk profiles.  This proposal could be supported 
by the studies on accreditation process of Australia5,  
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Singapore6, and Malaysia7, where differences in protocols, 
required documents, and processing duration were found 
among the countries depending on the mutual recognition 
arrangement ( MRA) , GMP certification, GMP regulatory 
agencies, manufacturing process, and types of finished 
pharmaceutical products.  These studies recommended risk 
management for the accreditation process which was 
consistent with the opinion from the three experts in our study 
where risk management should be implemented in the step of 
determining required documents to lessen the burden caused 
by requesting unnecessary documents.  
Second, there was a need for the mutual recognition 
arrangement (MRA) among countries. Once the trust between 
regulatory agencies among these countries are made, the 
sharing of knowledge and data and the acceptance or 
transferal of accreditation from the FDA of the manufacturer’s 
country could be possible.  With the MRA, the burden for on-
site inspection could be reduced which could further expedite 
the inspection process.  At present, Thailand has joined the 
ASEAN Sectorial Mutual Recognition Arrangement (MRA) for 
Good Manufacturing Practice ( GMP)  Inspection of 
Manufacturers of Medicinal Products which requests that all 
ASEAN members accept GMP Certificates and/ or GMP 
Inspection Reports according to PICS issued by the GMP 
inspectors in the ASEAN Listed Inspection Service. 8 Since 
Thailand has also joined PICS9, one of the FDA executive 
export asserted that such MRA could alleviate the burden of 
accreditation process and the time and expense for on- site 
inspection on oversea manufacturers.  The whole process of 
MRA is based on the trust in inspection standards shared by 
member countries.  
Third, an up- to-date database was proven again a vital 
part of all agencies.  FDA officers, import licensees, and an 
external expert all agreed that oversea manufacturers already 
accredited should be in the database. They also proposed the 
online E-submission system to reduce the burden of duplicate 
document submission and inspection especially those oversea 
manufacturers already accredited.  This was also consistent 
with the study of Tonmaithong where online electronic 
accreditation system (E-Accredit)  was found to offer a faster 
and more efficient accreditation of oversea manufacturers.10    
Fourth, the pre- submission consultation or advice for 
document preparation should be provided. This service could 
help reduce the premature withdrawal or cancellation of 
submission because of incomplete or defective document 
which was found as high as 91. 25%.  This proposed service 
could help reduce the burden on licensees for filing additional 
documents and the officers for reviewing such additional filing. 
This service should be independent from the document 
inspection process.  This proposal was sound since Australia 
has provided this kind of service for licensees.  In phase 2 of 
our study, an expert also supported the idea of having a 
consultation service system to prevent incomplete/ defective 
document submission.  The expert also stated that the plans 
for taskforce, rules, organization structure, and budget needed 
to be urgently made.   
Fifth, working efficiency among officers should be 
enhanced to overcome a lack of workforce and performance 
inconsistency among these officers.  Regarding a limited 
number of officers, 3 FDA executive experts had some 
disagreement. One of the three stated that there was relatively 
an adequate number of officers but efficiency was insufficient. 
However, the second expert argued that more data were 
needed to justify an appropriate number of officers; while the 
third expert agreed about the lack of officers.  However, all 
three FDA executive experts suggested that systematic 
thinking process should be introduced to the officers to 
enhance efficiency and information system fully implemented 
to reduce workload.  They also recommended a consultation 
service, online electronic leaning system, and outsourced 
freelance inspectors for oversea manufacturers to alleviate the 
problem of limited workforce.  Ultimately, they supported the 
idea of improving the officer’s efficiency as the first priority.  
In conclusion, results from our study could suggest certain 
practical points.  To improve understanding among import 
licensees, and reduce the cancellation on document 
submission, Thai FDA should develop more accessible routes 
for information, workflow, and document preparation which 
include public manuals/ leaflets, websites, and online E-
learning materials. To enhance efficiency of the FDA officers, 
database of oversea manufacturers should be developed for 
the use of the Pre- and Post-marketing Control Units. Last, to 
improve quality of other imported health-related products, FDA 
could also implement the proposed system found in our study.  
For future research, prospective studies should be done 
to prove efficiency of the new system for accreditation of 
oversea manufacturers.  Risks in the process of document 
preparation and submission for manufacturer’ s GMP should 
be studied.  Vigilance on quality of imported finished 
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pharmaceutical products from the accredited oversea 
manufacturers should be studied.  
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